Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

China Approves First HPV Vaccine But Can GSK Secure Its Lead?

Executive Summary

After a decade-long wait, China has finally approved its first HPV vaccine, GSK's Cervarix, handing a lead to the UK-based firm over its US competitor Merck in the world’s second largest pharma market. But with Chinese companies also vying for a slice of the pie, the battle is just beginning, and pricing will be a key element.

Advertisement

Related Content

Inovio Strikes First Partnership, In Emerging Markets, For Lead Product
Prevenar 13 Gains China OK But Challenges Remain
Diabetes Delivers China Strength For Merck
GSK Foresees Return To Emerging Markets Growth
Deep China Price Cuts Reveal Complex Considerations
GSK’s Witty: China Moving Rapidly To ‘No Growth’ Status

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register